Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | 1,2-dichloroethane | increases expression | ISO | Slc22a13 (Mus musculus) | 6480464 | ethylene dichloride results in increased expression of SLC22A13 mRNA | CTD | PMID:28960355 | 17alpha-ethynylestradiol | multiple interactions | ISO | Slc22a13 (Mus musculus) | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of SLC22A13 mRNA | CTD | PMID:17942748 | 17alpha-ethynylestradiol | increases expression | ISO | Slc22a13 (Mus musculus) | 6480464 | Ethinyl Estradiol results in increased expression of SLC22A13 mRNA | CTD | PMID:17942748 | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | Slc22a13 (Mus musculus) | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of SLC22A13 mRNA | CTD | PMID:17942748 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | Slc22a13 (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin results in increased expression of SLC22A13 mRNA | CTD | PMID:17942748 | aflatoxin B1 | decreases expression | ISO | Slc22a13 (Mus musculus) | 6480464 | Aflatoxin B1 results in decreased expression of SLC22A13 mRNA | CTD | PMID:19770486 | aflatoxin B1 | increases methylation | ISO | SLC22A13 (Homo sapiens) | 6480464 | Aflatoxin B1 results in increased methylation of SLC22A13 intron | CTD | PMID:30157460 | aristolochic acid A | increases expression | ISO | SLC22A13 (Homo sapiens) | 6480464 | aristolochic acid I results in increased expression of SLC22A13 mRNA | CTD | PMID:33212167 | arsane | affects methylation | ISO | SLC22A13 (Homo sapiens) | 6480464 | Arsenic affects the methylation of SLC22A13 gene | CTD | PMID:25304211 | arsenic atom | affects methylation | ISO | SLC22A13 (Homo sapiens) | 6480464 | Arsenic affects the methylation of SLC22A13 gene | CTD | PMID:25304211 | benzo[a]pyrene | affects methylation | ISO | SLC22A13 (Homo sapiens) | 6480464 | Benzo(a)pyrene affects the methylation of SLC22A13 intron | CTD | PMID:30157460 | benzo[a]pyrene | increases methylation | ISO | SLC22A13 (Homo sapiens) | 6480464 | Benzo(a)pyrene results in increased methylation of SLC22A13 3' UTR and Benzo(a)pyrene results in increased methylation of SLC22A13 promoter | CTD | PMID:27901495 | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of SLC22A13 mRNA | CTD | PMID:25181051 more ... | CGP 52608 | multiple interactions | ISO | SLC22A13 (Homo sapiens) | 6480464 | CGP 52608 promotes the reaction [RORA protein binds to SLC22A13 gene] | CTD | PMID:28238834 | cyclosporin A | decreases expression | EXP | | 6480464 | Cyclosporine results in decreased expression of SLC22A13 mRNA | CTD | PMID:21865292 | disodium selenite | decreases expression | ISO | SLC22A13 (Homo sapiens) | 6480464 | Sodium Selenite results in decreased expression of SLC22A13 mRNA | CTD | PMID:18175754 | methamphetamine | multiple interactions | EXP | | 6480464 | [Methamphetamine co-treated with SCH 23390] results in decreased expression of SLC22A13 mRNA | CTD | PMID:19564919 | methamphetamine | decreases expression | EXP | | 6480464 | Methamphetamine results in decreased expression of SLC22A13 mRNA | CTD | PMID:19564919 | methotrexate | increases expression | ISO | SLC22A13 (Homo sapiens) | 6480464 | Methotrexate results in increased expression of SLC22A13 mRNA | CTD | PMID:24449571 | ochratoxin A | decreases expression | EXP | | 6480464 | ochratoxin A results in decreased expression of SLC22A13 mRNA | CTD | PMID:30449730 | paracetamol | affects expression | ISO | Slc22a13 (Mus musculus) | 6480464 | Acetaminophen affects the expression of SLC22A13 mRNA | CTD | PMID:17562736 | paracetamol | decreases expression | ISO | SLC22A13 (Homo sapiens) | 6480464 | Acetaminophen results in decreased expression of SLC22A13 mRNA | CTD | PMID:26690555 | pirinixic acid | increases expression | ISO | Slc22a13 (Mus musculus) | 6480464 | pirinixic acid results in increased expression of SLC22A13 mRNA | CTD | PMID:20813756 | pyrazinecarboxamide | decreases expression | EXP | | 6480464 | Pyrazinamide results in decreased expression of SLC22A13 mRNA | CTD | PMID:22431067 | SCH 23390 | decreases expression | EXP | | 6480464 | SCH 23390 results in decreased expression of SLC22A13 mRNA | CTD | PMID:19564919 | SCH 23390 | multiple interactions | EXP | | 6480464 | [Methamphetamine co-treated with SCH 23390] results in decreased expression of SLC22A13 mRNA | CTD | PMID:19564919 | sirolimus | decreases expression | EXP | | 6480464 | Sirolimus results in decreased expression of SLC22A13 mRNA | CTD | PMID:21865292 | tacrolimus hydrate | decreases expression | EXP | | 6480464 | Tacrolimus results in decreased expression of SLC22A13 mRNA | CTD | PMID:21865292 | titanium dioxide | decreases expression | ISO | Slc22a13 (Mus musculus) | 6480464 | titanium dioxide results in decreased expression of SLC22A13 mRNA | CTD | PMID:29264374 | Triptolide | decreases expression | EXP | | 6480464 | triptolide results in decreased expression of SLC22A13 protein | CTD | PMID:32519852 | triptonide | increases expression | ISO | Slc22a13 (Mus musculus) | 6480464 | triptonide results in increased expression of SLC22A13 mRNA | CTD | PMID:33045310 | vancomycin | increases expression | ISO | Slc22a13 (Mus musculus) | 6480464 | Vancomycin results in increased expression of SLC22A13 mRNA | CTD | PMID:18930951 | |